CN1338309A - Synthetic peptide vaccine of hog cholera and its preparing process - Google Patents
Synthetic peptide vaccine of hog cholera and its preparing process Download PDFInfo
- Publication number
- CN1338309A CN1338309A CN00121291A CN00121291A CN1338309A CN 1338309 A CN1338309 A CN 1338309A CN 00121291 A CN00121291 A CN 00121291A CN 00121291 A CN00121291 A CN 00121291A CN 1338309 A CN1338309 A CN 1338309A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- polypeptide
- hog cholera
- synthetic peptide
- swine fever
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/187—Hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
A synthetic peptide vaccine of hog cholera contains at least one polypeptide which is coupled to carrier protein or carrier polypeptide to form conjugate and contains the neutralizing or variant epitope on cell membrane protein E2 of hog cholera virus. The process for preparing said vaccine includes synthesizing the polypeptide containing neutralizing epitope in antigen area, coupling it to carrier protein or carrier polypeptide to form conjugate, and adding auxiliary agent to obtain said vaccine. Said vaccine can effectively treat the variation of hog cholera virus.
Description
The present invention relates to vaccine with the biotechnology preparation and preparation method thereof, particularly relate to a kind of classical swine fever virus vaccine and preparation method thereof.
Swine fever is that (HCV) the pernicious communicate illness of Yin Faing is in case outburst often brings enormous economic loss at short notice for Classical Swine fever virus, CSFV or Hog Choleravirus by swine fever virus.As far back as the fifties, China has just developed hog cholera lapinised virus vaccine, this vaccine is a kind of of attenuated live vaccine, utilize the live hog Pestivirus behind the attenuation to come the induction of immunity protection, controlled swine fever being very popular and distributing effectively in China, fine because of its safety and preventive effect, many countries also use this vaccine.Enter the later stage seventies, swine fever popular with distribute with chronic infection be feature, and the immuning failure phenomenon generally appears.Fact proved, when the swine fever that the swine fever virus that existing hog cholera lapinised virus vaccine morphs at pre-Radix Stephaniae Tetrandrae causes is popular, exist very big difficulty.The swine fever virus subunit vaccine is a kind of swine Fever Vaccine of developing both at home and abroad at present, and this vaccine is to utilize the virus envelope protein of gene recombinaton to come the induction of immunity protection.Though this vaccine can tackle the variation of swine fever virus to a certain extent, only comprise a hereditary information of virus in the vaccine, when virus morphed, this vaccine promptly can lose effectiveness, and the production cost of this vaccine is still higher at present.
On the other hand, the antigenic region sequence on the swine fever virus envelope protein E 2 (690-866 amino acids residue) be proved can induction of immunity protection, (Vaccine 2000,18:2351 can to protect the infection of pig prevention swine fever virus; Vaccine 1999,17:433; J.Virology 1995,69:6479; Vaccine 2000,18:1374; J.Virology 1993,67:5435).
The purpose of this invention is to provide a kind of classical swine fever virus vaccine that can do with the swine fever virus variation.
Another object of the present invention provides a kind of method of producing above-mentioned classical swine fever virus vaccine.
For achieving the above object, the present invention takes following design: a kind of synthetic peptide vaccine of hog cholera, it comprise at least one be coupled on carrier protein or the carrier polypeptide form coupling matter include the neutralizing epitope on the swine fever virus envelope protein E 2 or the polypeptide of variant epitope.
Neutralizing epitope on the described swine fever virus envelope protein E 2 or variant epitope are positioned at the antigenic region on the swine fever virus envelope protein E 2.
More particularly, described antigenic region is the 690-866 amino acids residue on the swine fever virus envelope protein E 2.
The polypeptide of above-mentioned neutralizing epitope and variant epitope can be selected from following peptide sequence:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CNHNLQLDDGTVKAICMAGSFKVT
CNHDLQLNDGTVKASCVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
CSLHKKALPTSVTFELLFDGTN
CSLHKEALPTSVTFELLFDGTN
In order to make vaccine can resist the generation of sudden change better, the coupling matter of above-mentioned 9 polypeptide and carrier formation all can be joined in the vaccine.
In order to be suitable for injection, also should comprise acceptable medicinal adjuvant in the vaccine.
A kind of method for preparing above-mentioned synthetic peptide vaccine of hog cholera consists essentially of following steps:
(1), synthetic at least one contains the polypeptide of antigenic region neutralizing epitope on the swine fever virus envelope protein E 2 and/or variant epitope respectively;
(2), aforementioned polypeptides is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), above-mentioned coupling matter is equipped with acceptable adjuvant and is prepared into synthetic peptide vaccine of hog cholera.
It is stronger that the present invention utilizes the neutralizing epitope on the swine fever virus envelope protein E 2 can induce pig to produce, and the time is than the characteristic of long immune protection, at the more characteristics of swine fever virus variation, the utilization multiple vaccines makes pig produce multiple antibody to swine fever virus, that is to say, when one or several epi-position of swine fever virus morphs, the pig of having injected vaccine be enough in addition to tackle this variation swine fever virus corresponding to other antibody of variant epitope not.Vaccine of the present invention has the following advantages: 1, this vaccine is a kind of efficient multiple vaccines that can stimulate the multiple neutralizing antibody of generation, can effectively tackle the variation of virus, and then overcomes existing swine Fever Vaccine preventive effect difference even invalid shortcoming.2, the effective ingredient of this vaccine be coupled on carrier protein or the carrier polypeptide form coupling matter include the neutralizing epitope on the swine fever virus envelope protein E 2 or the epitope polypeptide of variant epitope, these epitope polypeptides do not need the native protein of the pathogen or the pathogen of attenuation or deactivation, the nucleic acid that does not also need gene recombinant protein antigen and pathogen, can directly induce predetermined, a plurality of neutralizing epitopes and variant epitope antigen-specific immune responses, the hereditary material and the activity that do not have swine fever virus, can not produce the side effect that the hereditary material because of swine fever virus brings out, there is not the danger of inactivated vaccine or attenuated vaccine possibility renaturation yet, also can get rid of simultaneously and use swine fever attenuated vaccine (as hog cholera lapinised virus vaccine) boar, induce in sow and the barren sow body generation swine fever attenuated live virus infection and duplicate, thereby overcome swine fever attenuated live viral infection barren sow to the mankind bring potential, unknown at present harm.3, can induce very strong immunne response at specific neutralizing epitope, be the inductive specific neutralizing antibody level of corresponding subunit vaccine 10-20 doubly, be 10-240 mcg/ml serum at the antibody amount of specific neutralizing epitope.4, according to the variation of swine fever virus, can produce the vaccine of its respective type very soon, need not test for a long time, reduce production costs.This technology will produce significant impact to world's preventive medicine research, will make the technology of preparing of classical swine fever virus vaccine produce revolutionary variation, and will bring huge economic benefit and social benefit.
The invention will be further described below in conjunction with specific embodiment.
Embodiment 1, preparation are based on the multi-joint-swine fever polypeptide of swine fever virus E2 albumen (synthesizing peptide) vaccine
1. synthetic contains 5 synthetic peptides (polypeptide) of one of neutralizing epitope in the swine fever virus E2 proteantigen district (690-866 amino acids residue) respectively, and the sequence of these 5 polypeptide is overlapped mutually, and the sequence of 5 polypeptide is:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) that aforementioned polypeptides is joined with carrier protein BSA coupling respectively;
3. above-mentioned 5 kinds of coupling matters are equipped with adjuvant (as oily adjuvant etc.) respectively and are prepared into multi-joint-swine fever polypeptide vaccine.Wherein, the variation probability in the portion rate of 5 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Embodiment 2, preparation based on the resistance of swine fever virus E2 albumen different-multi-joint-swine fever polypeptide (synthesize peptide) vaccine
1. synthetic contains 3 synthetic peptides (polypeptide) of swine fever virus E2 proteantigen district's neutralizing epitope and variant epitope respectively, and its sequence is:
CSHDLQLNDGTVKAICVAGSFKVT
CNHNLQLDDGTVKAICMAGSFKVT
CNHDLQLNDGTVKASCVAGSFKVT
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) that aforementioned polypeptides is joined with carrier protein bovine serum albumin coupling respectively;
3. above-mentioned 3 kinds of coupling matters are equipped with oily adjuvant respectively and are prepared into multi-joint-swine fever polypeptide vaccine.Wherein, the variation probability in the portion rate of 3 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Embodiment 3, preparation are based on the swine fever polypeptide of swine fever virus E2 albumen (synthesizing peptide) vaccine
1. synthetic contains 1 synthetic peptide of swine fever virus E2 proteantigen district neutralizing epitope, and its sequence is:
CKEDYRYAISSTNEIGLLGAGGLT
2. utilize glutaraldehyde with aforementioned polypeptides and carrier protein chicken ovalbumin coupling connection;
3. above-mentioned coupling matter is equipped with oily adjuvant and is prepared into the swine fever polypeptide vaccine.
Embodiment 4, preparation based on the resistance of swine fever virus E2 albumen different-multi-joint-swine fever polypeptide (synthesize peptide) vaccine
1. synthetic contains 9 synthetic peptides (polypeptide) of swine fever virus E2 proteantigen district's neutralizing epitope and variant epitope respectively, and its sequence is:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CNHNLQLDDGTVKAICMAGSFKVT
CNHDLQLNDGTVKASCVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
CSLHKKALPTSVTFELLFDGTN
CSLHKEALPTSVTFELLFDGTN
2. utilize MBS (m-maleimidobenzoyl-N-hydroxy succinimide ester) that aforementioned polypeptides is joined with carrier protein bovine serum albumin coupling respectively;
3. above-mentioned 9 kinds of coupling matters are equipped with respectively oily adjuvant be prepared into resistance different-multi-joint-swine fever polypeptide vaccine.Wherein, the variation probability in the portion rate of 9 kinds of coupling matters each site that can draw according to the different year statistical procedures is adjusted.
Claims (9)
1, a kind of synthetic peptide vaccine of hog cholera, it comprise at least one be coupled on carrier protein or the carrier polypeptide form coupling matter include the neutralizing epitope on the swine fever virus envelope protein E 2 or the polypeptide of variant epitope.
2, synthetic peptide vaccine of hog cholera according to claim 1 is characterized in that: neutralizing epitope on the described swine fever virus envelope protein E 2 or variant epitope are positioned at the antigenic region on the swine fever virus envelope protein E 2.
3, synthetic peptide vaccine of hog cholera according to claim 2 is characterized in that: described antigenic region is the 690-866 amino acids residue on the swine fever virus envelope protein E 2.
4, according to claim 1 or 2 or 3 described synthetic peptide vaccine of hog cholera, it is characterized in that: the polypeptide of described neutralizing epitope and variant epitope is selected from:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CNHNLQLDDGTVKAICMAGSFKVT
CNHDLQLNDGTVKASCVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
CSLHKKALPTSVTFELLFDGTN
CSLHKEALPTSVTFELLFDGTN
5, synthetic peptide vaccine of hog cholera according to claim 4 is characterized in that: described vaccine comprises following nine polypeptide that are coupled to formation coupling matter on carrier protein or the carrier polypeptide respectively:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CNHNLQLDDGTVKAICMAGSFKVT
CNHDLQLNDGTVKASCVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
CSLHKKALPTSVTFELLFDGTN
CSLHKEALPTSVTFELLFDGTN
6, according to claim 1 or 2 or 3 or 5 described synthetic peptide vaccine of hog cholera, it is characterized in that: also comprise acceptable medicinal adjuvant in the vaccine.
7, synthetic peptide vaccine of hog cholera according to claim 4 is characterized in that: also comprise acceptable medicinal adjuvant in the vaccine.
8, a kind of method for preparing above-mentioned synthetic peptide vaccine of hog cholera consists essentially of following steps:
(1), synthetic at least one contains the polypeptide of antigenic region neutralizing epitope on the swine fever virus envelope protein E 2 and/or variant epitope respectively;
(2), aforementioned polypeptides is coupled to respectively on carrier protein or the carrier polypeptide forms coupling matter;
(3), above-mentioned coupling matter is equipped with acceptable adjuvant and is prepared into synthetic peptide vaccine of hog cholera.
9, a kind of method for preparing synthetic peptide vaccine of hog cholera according to claim 8, it is characterized in that: the polypeptide that contains antigenic region neutralizing epitope on the swine fever virus envelope protein E 2 of described synthetic is selected from:
CKEDYRYAISSTNEIGLLGAGGLT
CAGGLTTTWKEYSHDLQ
CSHDLQLNDGTVKAICVAGSFKVT
CSFKVTALNVVSRRYLASLHK
CSLHKGALLTSVTFELLFDGTN
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00121291A CN1338309A (en) | 2000-08-10 | 2000-08-10 | Synthetic peptide vaccine of hog cholera and its preparing process |
| AU2002223384A AU2002223384A1 (en) | 2000-08-10 | 2001-07-20 | Synthetic peptide hog cholera vaccine and method producing it |
| PCT/CN2001/001188 WO2002032453A1 (en) | 2000-08-10 | 2001-07-20 | Synthetic peptide hog cholera vaccine and method producing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00121291A CN1338309A (en) | 2000-08-10 | 2000-08-10 | Synthetic peptide vaccine of hog cholera and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1338309A true CN1338309A (en) | 2002-03-06 |
Family
ID=4588704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00121291A Pending CN1338309A (en) | 2000-08-10 | 2000-08-10 | Synthetic peptide vaccine of hog cholera and its preparing process |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1338309A (en) |
| AU (1) | AU2002223384A1 (en) |
| WO (1) | WO2002032453A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152570B (en) * | 2007-10-19 | 2010-11-24 | 清华大学 | Epitope vaccine of hog cholera virus and its preparing process |
| CN101144818B (en) * | 2007-10-19 | 2011-04-27 | 清华大学 | Method for detecting pig plague virus specific antibody and its ELISA reagent kit |
| CN102485749A (en) * | 2009-10-09 | 2012-06-06 | 中牧实业股份有限公司 | Swine fever synthesized peptide vaccine and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23544A1 (en) | 2006-02-28 | 2010-06-17 | Ct Ingenieria Genetica Biotech | CHEMICAL VACCINAL ANTIGENS AGAINST THE CLASSICAL SWINE VIRUS VIRUS |
| CN110652583A (en) * | 2018-06-29 | 2020-01-07 | 西北民族大学 | Bivalent inactivated antigen of swine foot-and-mouth disease and swine fever low virulent strain bigeminy vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE870507L (en) * | 1986-03-07 | 1987-09-07 | Biothechnological Res Partners | Bovine virus diarrhea and hog cholera vaccines |
| ZA901719B (en) * | 1989-03-19 | 1991-01-30 | Akzo Nv | Hog cholera virus vaccine and diagnostics |
| HU220746B1 (en) * | 1994-06-17 | 2002-05-28 | Instituut Voor Veehouderij En Diergezondheid | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections |
| DK0772632T3 (en) * | 1994-12-20 | 2001-12-31 | Akzo Nobel Nv | T-cell stimulating protein of pestivirus |
| EP0982402A1 (en) * | 1998-08-14 | 2000-03-01 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Pestivirus vaccination |
-
2000
- 2000-08-10 CN CN00121291A patent/CN1338309A/en active Pending
-
2001
- 2001-07-20 AU AU2002223384A patent/AU2002223384A1/en not_active Abandoned
- 2001-07-20 WO PCT/CN2001/001188 patent/WO2002032453A1/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152570B (en) * | 2007-10-19 | 2010-11-24 | 清华大学 | Epitope vaccine of hog cholera virus and its preparing process |
| CN101144818B (en) * | 2007-10-19 | 2011-04-27 | 清华大学 | Method for detecting pig plague virus specific antibody and its ELISA reagent kit |
| CN102485749A (en) * | 2009-10-09 | 2012-06-06 | 中牧实业股份有限公司 | Swine fever synthesized peptide vaccine and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002032453A1 (en) | 2002-04-25 |
| AU2002223384A1 (en) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4474757A (en) | Synthetic vaccine and process for producing same | |
| WO2021248853A1 (en) | Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof | |
| CN104262488B (en) | A kind of preparation and application of fusion protein and its vaccine combination | |
| EP1745798A2 (en) | Hcv vaccine compositions | |
| CN1091978A (en) | CSF 393000 is as the purposes of vaccine adjuvant | |
| CN1241639C (en) | Vaccine composition against malaria | |
| WO2021254287A1 (en) | Novel coronavirus tandem epitope polypeptide vaccine and use thereof | |
| CN1665528A (en) | Adjuvant viral particle | |
| CA2066661A1 (en) | Viral vaccine conjugates | |
| EP0235391B1 (en) | Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses | |
| CN1338310A (en) | Epitope vaccine of hog cholera virus and its preparing process | |
| KR20070048140A (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
| CN1338309A (en) | Synthetic peptide vaccine of hog cholera and its preparing process | |
| CN1195993A (en) | Intranasal vaccination against gastrointestinal disease | |
| CN1323222A (en) | LT and CT in parenteral immunization methods against helicobacter infection | |
| CA1214103A (en) | Lectin-containing anti-viral vaccines for domestic animals and method of preparation | |
| RU2007106900A (en) | IMMUNOGENIC COMPLEXES, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION IN PHARMACEUTICAL COMPOSITIONS | |
| AU633851B2 (en) | Pharmaceutical compositions for eliciting an immunostimulant effect | |
| CN1163271C (en) | Synthetic peptide vaccine of influenzand its preparing process | |
| CN113248575B (en) | Recombinant protein vaccine for SARS-CoV-2 and its preparing method | |
| CN1108820C (en) | Preparation of epitope vaccine with single monoepitope or multiple monoepitope duplication | |
| CN1408349A (en) | Foot-and-mouth disease gene engineering polypeptide vaccine and its preparing method | |
| CN105481953A (en) | Target cell specificity fusion protein serving as porcine reproductive and respiratory syndrome viral vaccine antigen and vaccine composition | |
| CN1338307A (en) | Epitope vaccine of influenza virus and its preparing process | |
| NZ250555A (en) | Vaccine with enhanced immunogenicity by inclusion of a cytokine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |